These results suggest that blocking NF-kB signaling, such as inhibiting IKK, an upstream activator of NF-kB, could potentially improve the efficacy of BH3-mimetic drugs or chemotherapeutic agents in killing cancer cells. This evidence concerns the gene NFKB1 and cancer.